ArticleOncology letters2019
LINK-A lncRNA functions in the metastasis of osteosarcoma by upregulating HIF1α.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.NPJ precision oncology · 2024Review
- Emerging roles of long non-coding RNAs in osteosarcoma.Frontiers in molecular biosciences · 2024Review
- A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors.Journal of Cancer · 2024Review
- LINK-A: unveiling its functional role and clinical significance in human tumors.Frontiers in cell and developmental biology · 2024Review
- Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis.Frontiers in pharmacology · 2024Review
- LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.Frontiers in endocrinology · 2024Review
- Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.Cancers · 2022Review
- Downregulation of miR-491-5p promotes neovascularization after traumatic brain injury.Neural regeneration research · 2022Article
- The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets.Frontiers in cell and developmental biology · 2022Review
- Increased long noncoding RNA LINK-A contributes to rheumatoid synovial inflammation and aggression.JCI insight · 2021Article
- Circulating lncRNAs HIF1A-AS2 and LINLK-A: Role and Relation to Hypoxia-Inducible Factor-1α in Cerebral Stroke Patients.Molecular neurobiology · 2021Article
- Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma.Cancers · 2021Review
- Article
- Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer.Non-coding RNA · 2020Review
- Long noncoding RNAs in osteosarcoma via various signaling pathways.Journal of clinical laboratory analysis · 2020Review
- LncRNA LINK-A regulates ROCK1 expression in early-stage pancreatic adenocarcinoma.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long intergenic non-coding RNA for kinase activation (LINK-A) long non-coding RNA (lncRNA) is an oncogenic lncRNA in triple-negative breast cancer. The involvement of LINK-A lncRNA in other diseases is unknown. The present study aimed to investigate the possible involvement of LINK-A lncRNA in osteosarcoma. The results demonstrated that plasma levels of LINK-A lncRNA were significantly higher in patients with metastatic osteosarcoma (MO) compared with healthy controls and patients with non-metastatic osteosarcoma (NMO). LINK-A lncRNA overexpression significantly promoted cancer cell migration and invasion in osteosarcoma cell lines MG-63 and U20S. Upregulated expression of hypoxia-inducible factor 1α (HIF1α) was observed in cancer cells following LINK-A lncRNA overexpression. Exogenous HIF1α treatment did not significantly affect the expression of LINK-A lncRNA in cancer cells, whereas treatment with an HIF1α inhibitor significantly attenuated the effects of LINK-A lncRNA overexpression on cancer cell migration and invasion. Based on the results it was concluded that LINK-A lncRNA participated in the metastasis of osteosarcoma by upregulating HIF1α; upregulation of LINK-A lncRNA may serve as a potential diagnostic biomarker for patients with MO but not in those with NMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.